15 Sep 2015

Read the full release

Stockholm, Sweden, 15 September 2015 - New findings from the DUAL(TM) V phase 3b clinical trial showed greater improvements in treatment-related satisfaction and patient-reported physical health in people treated with Xultophy® versus insulin glargine U100. The DUAL(TM) V trial evaluated the efficacy and safety of Xultophy® (IDegLira), a once-daily single-injection combination of Tresiba® (insulin degludec) and Victoza® (liraglutide) compared to further intensification with insulin glargine U100 in adults with type 2 diabetes uncontrolled on insulin glargine U100.

Further information

distributed by